
David M Nanus MD
Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine Director of New York Presbyterian Hospital - Weill Cornell Medicine Healthcare Systems Cancer Program Associate Director for Clinical Services Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
520 E 70th St# StarrNew York, NY 10021
Fax+1 646-962-1603
Overview of Dr. Nanus
I am the Director of New York Presbyterian Hospital - Weill Cornell Medicine Healthcare Systems Cancer Program and the Associate Director for Clinical Services in the Meyer Cancer Center at Weill Cornell Medicine. I was Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College – New York Presbyterian Hospital for a5 years from 2004-2019. I am also the Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine and Professor of Medicine and Urology. I completed my clinical training in Medicine at Albert Einstein College of Medicine followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center, and research training at the Sloan Kettering Institute. I joined the faculty at Memorial Sloan Kettering Cancer Center in 1989 as a physician scientist and was recruited to the full-time faculty of Weill Cornell Medical College in 1998. My clinical focus is the treatment and care of patients with genitourinary (GU) cancers, and I am actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of grants and clinical research trials that incorporate novel targeted therapies for patients, working closely with physicians and scientists.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1983 - 1985
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1982 - 1983
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1982
University of Illinois at Urbana-ChampaignB.S., 1974 - 1978
Certifications & Licensure
NY State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- Member American Association of Physicians, 2005
Clinical Trials
- Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 1999 Jan 01
- Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer Start of enrollment: 2005 Jun 03
- Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2003 Jul 01
Publications & Presentations
PubMed
- Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort.Majd Al Assaad, Kevin Hadi, Max F Levine, Daniela Guevara, Minal Patel
Communications Medicine. 2026-01-12 - 1 citationsDocetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.Pedro C Barata, June K Corrigan, Jennifer La, John M Culnan, Elliot Akama-Garren
JAMA Network Open. 2026-01-02 - Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance.Matthew R Cooperberg, John R Bihn, John M Culnan, Jennifer La, Sergey D Goryachev
JAMA Oncology. 2026-01-01
Journal Articles
- Analyses of the transcriptome and metabolome demonstrate that HIF1alpha mediates altered tumor metabolism in clear cell renal cell carcinomaMinton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, Gudas LJ, Plos One, 1/1/2015
- Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTA- huJ591 anti prostate specific membrane antigen specific monoclonal antibodyVallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ, Curr Radiopharm, 1/1/2015
- Genome-wide Profiling of TRACK kidneys shows similarity to the human ccRCC transcriptomeFu L, Minton DR, Zhang T, Nanus DM, Gudas LJ, Mol Cancer Res, 1/1/2015
Books/Book Chapters
Press Mentions
Finding Innovative Ways to Address Kidney Cancer Leads to DoD GrantDecember 10th, 2024
How a Novel Genomic Analysis Leveraged Whole-Exome and RNA Sequencing to Save the Life of an Elderly PatientJuly 16th, 2024
How to Find Support When You Have Metastatic Kidney CancerApril 25th, 2023
Grant Support
- Phase II Trial Of 177lu-J591 In Metastatic, Androgen-Independent Prostate CancerNational Center For Research Resources2007
- Phase I Trial Of ATRA-IV &Depakote In PTS W/Advanced Solid Tumor MalignanciesNational Center For Research Resources2005–2006
- Modulation Of Retinoic Acid Action In Renal CancerNational Cancer Institute2001–2005
- Neutral Endopeptidase Inactivation In Advanced ProstateNational Cancer Institute1998–2005
- Phase I 111-Indium Radiolabeled MAB Huj591/ Metastatic Solid TumorsNational Center For Research Resources2004
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
First Health PPO
GHI PPO
Great West PPO
Health Net Oregon PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








